Alumis (NASDAQ:ALMS) Director Srinivas Akkaraju Acquires 588,235 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) Director Srinivas Akkaraju acquired 588,235 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director owned 1,853,488 shares of the company’s stock, valued at $31,509,296. This represents a 46.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Srinivas Akkaraju also recently made the following trade(s):

• On Friday, December 5th, Srinivas Akkaraju bought 186,377 shares of Alumis stock. The stock was purchased at an average cost of $9.84 per share, for a total transaction of $1,833,949.68.
• On Thursday, December 4th, Srinivas Akkaraju purchased 66,027 shares of Alumis stock. The shares were purchased at an average cost of $8.18 per share, with a total value of $540,100.86.
• On Wednesday, December 3rd, Srinivas Akkaraju purchased 100,000 shares of Alumis stock. The shares were acquired at an average cost of $7.75 per share, with a total value of $775,000.00.
• On Tuesday, December 2nd, Srinivas Akkaraju acquired 96,000 shares of Alumis stock. The stock was acquired at an average cost of $7.55 per share, for a total transaction of $724,800.00.
• On Monday, December 1st, Srinivas Akkaraju bought 86,350 shares of Alumis stock. The shares were acquired at an average price of $7.46 per share, with a total value of $644,171.00.
• On Friday, November 28th, Srinivas Akkaraju bought 38,702 shares of Alumis stock. The stock was acquired at an average cost of $7.64 per share, with a total value of $295,683.28.
• On Wednesday, November 26th, Srinivas Akkaraju purchased 48,537 shares of Alumis stock. The stock was acquired at an average price of $7.64 per share, for a total transaction of $370,822.68.
• On Thursday, November 20th, Srinivas Akkaraju acquired 125,743 shares of Alumis stock. The shares were acquired at an average price of $7.20 per share, with a total value of $905,349.60.
• On Wednesday, November 19th, Srinivas Akkaraju acquired 137,772 shares of Alumis stock. The stock was bought at an average price of $6.56 per share, with a total value of $903,784.32.
• On Tuesday, November 18th, Srinivas Akkaraju bought 102,652 shares of Alumis stock. The shares were bought at an average price of $6.05 per share, for a total transaction of $621,044.60.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $22.11 on Wednesday. The stock has a 50 day moving average price of $9.90 and a 200 day moving average price of $6.21. The stock has a market capitalization of $2.31 billion, a PE ratio of -5.46 and a beta of -2.09. Alumis Inc. has a 52 week low of $2.76 and a 52 week high of $23.00.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The firm had revenue of $2.07 million during the quarter, compared to the consensus estimate of $3.14 million. As a group, research analysts forecast that Alumis Inc. will post -8.51 EPS for the current year.

Institutional Trading of Alumis

Several hedge funds have recently added to or reduced their stakes in the company. Samsara Biocapital LLC lifted its holdings in shares of Alumis by 47.0% during the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after buying an additional 1,534,872 shares in the last quarter. Foresite Capital Management VI LLC increased its position in Alumis by 1.1% during the second quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company’s stock worth $12,743,000 after acquiring an additional 45,000 shares during the period. Vanguard Group Inc. increased its position in Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after acquiring an additional 625,404 shares during the period. Trium Capital LLP raised its stake in Alumis by 17.9% in the 3rd quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after purchasing an additional 474,072 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new stake in Alumis in the 2nd quarter valued at about $5,779,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price (up from $20.00) on shares of Alumis in a report on Friday. Wall Street Zen upgraded Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Citigroup reaffirmed an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Wells Fargo & Company boosted their target price on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Finally, Leerink Partners raised their price target on Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Alumis presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju purchased 588,235 shares at $17.00 (≈$10.0M) on Jan. 9, increasing his stake to ~1.85M shares — a sizable insider buy that signals confidence from management. SEC Filing
• Positive Sentiment: Director James B. Tananbaum acquired 411,764 shares at $17.00 (≈$7.0M), raising his direct holdings to ~5.70M shares — another high‑profile insider transaction that supports bullish sentiment. SEC Filing
• Positive Sentiment: Major shareholder Foresite (Labs/Capital/Management entities) bought 411,764 shares at $17.00 (≈$7.0M), increasing its position — institutional support from a large investor typically boosts sentiment and liquidity. SEC Filing
• Neutral Sentiment: Analyst coverage has been upbeat recently (multiple firms reissued “outperform/buy” and several raised price targets), which likely amplified the impact of the insider/institutional buys. See company analyst summary and coverage. MarketBeat Coverage
• Neutral Sentiment: Reported short‑interest data appears anomalous (entries show 0 shares), so short‑interest signals are unreliable for current moves; investors should treat this data cautiously. Market Data
• Negative Sentiment: Fundamental caution: Alumis missed on the most recent reported quarter (Nov. 13) with EPS and revenue below consensus, and the company is still loss‑making — a reminder of execution and clinical risk that could limit upside if program results disappoint. Earnings/Background

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.